Search results
Sep 2, 2020 · These studies suggest a link between COVID-19 and GBS. At the time of writing this paper, approximately 31 cases of GBS associated with COVID-19 infection have been reported. This study showed that, on average, 11.92 ± 6.20 days after COVID-19 infection, the neurological symptoms of GBS begin.
Oct 23, 2023 · Existing data regarding occurrence of Guillain-Barré syndrome (GBS) after coronavirus disease 2019 (COVID-19) infection and vaccination are inconclusive. We aimed to assess the association between GBS and both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 vaccine.
Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ≈5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years ( 1 ). GBS has been reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking.
Oct 19, 2023 · A large new study links COVID-19 with an increased risk of Guillain-Barré syndrome (GBS). Vaccination against COVID appeared to reduce the risk of GBS, which is a rare illness that can...
Jan 17, 2023 · In recent months, a variety of studies and case reports have proposed an association between COVID-19 and Guillain–Barré syndrome (GBS). The present work aims to systematically review the publications available to date to verify the relationship between these two pathologies and the characteristics of post-COVID GBS.
Coronavirus disease 2019 (COVID-19) has been shown to be associated with a lot of neurological complications, of whom Guillain-Barre syndrome (GBS) is an important post-infectious consequentiality. More than 220 patients with GBS have been reported thus far.
Sep 7, 2021 · More extensive studies aimed at exploring the neurological manifestations and complications of COVID-19 and distinctive treatment options for COVID-19–related GBS are warranted. Key Words: COVID-19, coronavirus, Guillain-Barré syndrome, plasma exchange, intensive care units, immunotherapy, IVIG.
